BSX vs NPCE
BSX: Boston Scientific is a leading medical device company dedicated to transforming lives through innovative, less-invasive medical solutions for a broad range of interventional specialties. NPCE: NeuroPace is a medical device company providing the first brain-responsive neuromodulation system that treats drug-resistant epilepsy by delivering personalized, real-time therapy at the seizure source.
Side-by-side fundamentals
| Metric | BSX | NPCE | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $42.04 | $12.39 | |
| Market cap | $60.9B | $425M | |
| P/E as of 2026-10-08 | 17.05 | n/a | |
| PEG as of 2026-10-08, 3-year EPS CAGR to FY2025 | 0.27 | n/a | |
| Net margin FY2025, SEC XBRL | +14.4% | -21.5% | BSX higher |
| Gross margin FY2025, SEC XBRL | +69.0% | +77.2% | NPCE higher |
| Operating margin FY2025, SEC XBRL | +18.0% | -16.3% | BSX higher |
| ROE FY2025, SEC XBRL | +11.8% | -112.8% | BSX higher |
| ROA FY2025, SEC XBRL | +6.6% | -20.3% | BSX higher |
| Debt / equity as of 2026-09-03 | 0.51 | 4.08 | BSX lower |
| Revenue growth (YoY) as of 2026-09-03 | +13.5% | +18.1% | NPCE higher |
| Revenue CAGR (3y) SEC XBRL | +16.5% | +30.0% | NPCE higher |
| Dividend yield | n/a | n/a | |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 0.57 | 1.13 | |
| 1-year return as of 2026-10-08 close | -56.6% | +11.3% | NPCE higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.